Michael Amoroso compensation by year
ABEONA THERAPEUTICS Summary Compensation Table · all 2 fiscal years held| Component | FY2020 | FY2021 |
|---|---|---|
| Salary | $219,071 | $450,477 |
| Bonus | $106,400 | $0 |
| Stock awards | $338,728 | $1,013,000 |
| Option awards | $827,294 | $1,589,910 |
| Non-equity incentive | $0 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $7,667 | $11,600 |
| Total | $1,499,160 | $3,064,987 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ABEONA THERAPEUTICS INC. DEF 14A filed July 11, 2022, accession 0001140361-22-025707, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ABEONA THERAPEUTICS INC. filed document, accession 0001140361-22-025707. Every figure is read from that document and cited to the page and table it appears in. Filed July 11, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 10,000 | $85,000 | — |
| RSU | 8,000 | $68,000 | — |
| Option | 16,000 | — | $58.50 |
| Option | 20,000 | — | $54.50 |
| Option | 2,916 | — | $26.75 |
| Option | 6,458 | — | $28.75 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ABEONA THERAPEUTICS INC.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
10 Form 4 lines since the FY2021 proxy (filed July 11, 2022)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-01-26 | Grant or award | — | 37,313 | $0.00 | 217,779 |
| 2025-01-31 | Grant or award | — | 36,101 | $0.00 | 180,466 |
| 2024-08-26 | Grant or award | — | 11,797 | $0.00 | 144,365 |
| 2024-07-08 | Grant or award | — | 23,611 | $0.00 | 132,568 |
| 2023-09-27 | Sale | — | 5,508 | $3.91 | 108,957 |
| 2023-09-20 | Sale | — | 327 | $3.90 | 114,465 |
| 2023-06-20 | Sale | — | 338 | $4.45 | 114,792 |
| 2023-06-14 | Grant or award | — | 58,689 | $4.62 | 115,130 |
The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
ABEONA THERAPEUTICS’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Michael Amoroso · this page | Former President and Chief Executive Officer | $3,064,987 |
| Edward Carr | Former Chief Accounting Officer and Chief Financial Officer | $1,569,879 |
| Vishwas Seshadri | President and Chief Executive Officer | $1,566,475 |
| Brendan O’Malley | General Counsel | $1,179,209 |
Board service
ABEONA THERAPEUTICS board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $85,000 | $200,000 | — | $0 | $285,000 |
| FY2024 | $80,000 | $181,048 | — | $0 | $261,048 |
| FY2023 | $80,000 | $271,143 | — | $0 | $351,143 |
| FY2022 | $80,000 | $37,386 | — | — | $117,386 |
| FY2021 | $0 | $0 | $0 | — | — |
Each year as the company reported it in ABEONA THERAPEUTICS's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: ABEONA THERAPEUTICS pays directors a $50,000 cash retainer and $200,000 in Restricted Stock. As stated in ABEONA THERAPEUTICS's FY2025 proxy.
Committees
Nominating/Governance
The full ABEONA THERAPEUTICS compensation record
free company briefThis page is one person within ABEONA THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ABEONA THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.